SmallCapSentinel.com Releases Report for Investors of Medical Device Companies SENO, STXS, EVVV, ANGO, THOR, and CPTS

LAS VEGAS, June 10 /PRNewswire/ — SmallCapSentinel.com announces the availability of the report “A Growing Body of Evidence” related to the medical device industry featuring SenoRx, Inc. (NasdaqGM: SENO) and of interest to investors of Stereotaxis Inc. (NasdaqGM: STXS), ev3 Inc. (NasdaqGS: EVVV), AngioDynamics Inc. (NasdaqGS: ANGO), Thoratec Corp. (NasdaqGS: THOR) and Conceptus Inc. (NasdaqGM: CPTS).

To read the article “A Growing Body of Evidence” visit:

http://www.smallcapsentinel.com/SENO6-7

From the report: SenoRx, Inc. believes that a breast cancer patient treated with its Contura(TM) Multi-Lumen Balloon (MLB) receives a more targeted dose of radiation while minimizing radiation to healthy surrounding tissue such as the skin and ribs than those treated with whole breast irradiation or with a single-lumen balloon. A growing and compelling body of scientific data suggests SenoRx is right. Over the past few months data has been rolling in from experts and opinion leaders, research partners and clinical sites. A consensus is forming and the future for Contura MLB (and SenoRx) seems brighter than ever.

For an Integrity Media profile of SenoRx please visit: www.IntegrityIR.com/SENO

To view the related article, “Innovation and Speed to Market” visit:

http://integrityir.com/SENOSCS1

Register to receive these reports directly at: www.SmallCapSentinel.com/register

Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. Small Cap Sentinel is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company’s plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven’t always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn’t be used as basis for investment decisions. IMI isn’t an investment advisor, analyst or licensed broker dealer and this report isn’t investment advice. IMI has been paid thirty-thousand dollars by SenoRx for this report and other services to be performed over the remainder of the calendar year. Paid reports constitute a conflict of interest as to IMI’s ability to remain objective in communication regarding subject companies. S.Convery CRD #2495267.

    Contact:
    Kurt Divich, Editor
    Integrity Media Inc.
    702-396-1000

SOURCE Integrity Media